ADMA
ADMA Biologics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.62
+0.42%Aug 26, 2026, 13:26 UTC
Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of ADMA Biologics, Inc.
Source:Aug 15, 2026, 07:33 UTC
Bank of America Corp DE increased its stake in ADMA Biologics Inc by 107.5% during the quarter, acquiring an additional 2,071,338 shares, according to a recent SEC filing.
Source:Aug 6, 2026, 02:39 UTC
A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. alleging misrepresentations about its financial condition and business practices.
Aug 5, 2026, 22:05 UTC
ADMA Biologics reported second-quarter revenue growth of 2%, with increased sales of ASCENIV offsetting pressure on BIVIGAM.
Aug 1, 2026, 23:02 UTC
A securities class action lawsuit was filed against ADMA Biologics, Inc. alleging securities fraud, with a lead plaintiff deadline of August 10, 2026.
Source:Jul 15, 2026, 10:17 UTC
A class action lawsuit has been filed against ADMA Biologics and certain senior executives for securities fraud after a stock drop related to channel stuffing claims.
Jul 6, 2026, 17:57 UTC
A class action lawsuit was filed against ADMA Biologics, Inc. for alleged securities law violations under the Securities Exchange Act of 1934.
Jun 24, 2026, 13:24 UTC
A shareholder filed a securities class action lawsuit against ADMA Biologics, Inc. on behalf of investors who purchased its securities between August 9, 2024 and March 25, 2026.
Source: